NASDAQ:OTIC Otonomy (OTIC) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free OTIC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.0085▼$0.008550-Day Range$0.01▼$0.1252-Week Range$0.01▼$2.54VolumeN/AAverage Volume937,525 shsMarket Capitalization$582,479.50P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Ad The Freeport SocietyPOTUS in ‘25 Not Biden/Trump, ButAnd I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.Click here now to see my urgent election warning. About Otonomy Stock (NASDAQ:OTIC)Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.Read More Ad The Freeport SocietyPOTUS in ‘25 Not Biden/Trump, ButAnd I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.Click here now to see my urgent election warning. OTIC Stock News HeadlinesJanuary 23, 2023 | finance.yahoo.comOtonomy, Inc. (OTIC) Stock Historical Prices & Data - Yahoo FinanceDecember 21, 2022 | finanznachrichten.deOtonomy, Inc.: Otonomy Provides Corporate UpdateDecember 19, 2022 | finance.yahoo.comOtonomy Provides Corporate UpdateNovember 30, 2022 | investorplace.com5 Investors Betting Big on Otonomy (OTIC) StockNovember 29, 2022 | investorplace.comWhy Is Otonomy (OTIC) Stock Up 97% Today?November 10, 2022 | finance.yahoo.comOtonomy Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 6, 2022 | reuters.comOTIC.OQ - Otonomy Inc | Stock Price & Latest News | ReutersOctober 14, 2022 | marketscreener.comOTONOMY, INC. : Results of Operations and Financial Condition (form 8-K) - Marketscreener.comOctober 13, 2022 | investing.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.83% By Investing.com - Investing.comOctober 13, 2022 | finance.yahoo.comLianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial - Yahoo FinanceOctober 13, 2022 | streetinsider.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.83% - StreetInsider.comOctober 13, 2022 | benzinga.comOtonomy shares are trading lower after the company reported higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baseline. - Otonomy (NASDAQ:OTIC) - BenzingaOctober 13, 2022 | marketscreener.comOtonomy Sees No Clinically Meaningful Improvement With Higher Doses of OTO-413 in Patients With Hearing Loss -- Shares Nosedive - Marketscreener.comOctober 13, 2022 | benzinga.comWhy Laser Photonics Shares Are Trading Higher By Around 44%, Here Are 50 Stocks Moving In Thursday’s Mid- - BenzingaOctober 13, 2022 | marketscreener.comOtonomy Sees No Clinically Meaningful Improvement With Higher Doses of OTO-413 in Patients With Hearing Loss - Marketscreener.comOctober 13, 2022 | globenewswire.comOtonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss - GlobeNewswireOctober 13, 2022 | finance.yahoo.comOtonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss - Yahoo FinanceOctober 13, 2022 | finance.yahoo.comOtonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing LossOctober 7, 2022 | reuters.comOTIC.O - Otonomy Inc | Stock Price & Latest News | ReutersSeptember 27, 2022 | marketscreener.comAPPLIED GENETIC TECHNOLOGIES CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.comSeptember 17, 2022 | marketscreener.comOTONOMY, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - Marketscreener.comSeptember 9, 2022 | streetinsider.comForm SC 13G/A OTONOMY, INC. Filed by: FEDERATED HERMES, INC. - StreetInsider.comSeptember 1, 2022 | finance.yahoo.comAGTC to Participate in Upcoming Investor Conferences - Yahoo FinanceAugust 11, 2022 | marketscreener.comOtonomy : Costs Associated with Exit or Disposal Activities - Form 8-K - Marketscreener.comAugust 9, 2022 | marketscreener.comOTONOMY, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K) - Marketscreener.comSee More Headlines Company Calendar Last Earnings11/10/2021Today5/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OTIC CUSIPN/A CIK1493566 Webwww.otonomy.com Phone(619) 323-2200Fax619-291-9190Employees51Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-137.86% Return on Assets-68.50% Debt Debt-to-Equity RatioN/A Current Ratio1.74 Quick Ratio1.74 Sales & Book Value Annual Sales$130,000.00 Price / Sales4.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book0.01Miscellaneous Outstanding Shares68,527,000Free Float67,780,000Market Cap$582,479.50 OptionableOptionable Beta1.54 Key ExecutivesPaul E. CayerPresident, CFO, Secretary & Chief Business OfficerAnna StepannenkoVice President -Technical operationsFabrice PiuVice President-Research & Preclinical DevelopmentDavid SkarinskyVice President-ClinicalJeffery J. AndersonVice President-Clinical SciencesKey CompetitorsAditxtNASDAQ:ADTXComera Life SciencesNASDAQ:CMRAChina SXT PharmaceuticalsNASDAQ:SXTCBellerophon TherapeuticsNASDAQ:BLPHAptevo TherapeuticsNASDAQ:APVOView All Competitors OTIC Stock Analysis - Frequently Asked Questions How were Otonomy's earnings last quarter? Otonomy, Inc. (NASDAQ:OTIC) released its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). During the same quarter in the previous year, the company earned ($0.22) earnings per share. What other stocks do shareholders of Otonomy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie (). This page (NASDAQ:OTIC) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsMost important medical advance in 100 yearsThe Oxford ClubThe Presidential candidate you should REALLY be worried aboutStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
